AI Analysis | Feedback

Here are 1-3 brief analogies for Tenaya Therapeutics (TNYA):

• Vertex Pharmaceuticals for genetic heart diseases.

• Sarepta Therapeutics for genetic heart diseases.

• A specialized Regeneron Pharmaceuticals, entirely dedicated to developing innovative treatments for heart disease.

AI Analysis | Feedback

• TN-201: An AAV-based gene therapy designed to treat genetic hypertrophic cardiomyopathy (gHCM) caused by MYBPC3 gene mutations.
• TN-301: A small molecule inhibitor (HDAC6i) aimed at treating heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).
• TN-401: An AAV-based gene therapy targeting genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by PKP2 gene mutations.
• DWORF gene therapy: An AAV-based gene therapy intended to deliver the dwarf open reading frame (DWORF) gene to the heart for dilated cardiomyopathy (DCM).
• Reprogramming program: An AAV-based approach for cardiac regeneration to replace heart cells lost in patients with heart failure due to myocardial infarction.

AI Analysis | Feedback

Tenaya Therapeutics (TNYA) is a biotechnology company primarily engaged in the discovery, development, and delivery of therapies for heart disease. As a pre-commercial stage company focused on research and development of drug candidates (e.g., TN-201, TN-301, TN-401), Tenaya Therapeutics does not currently have major customers in the traditional sense of selling commercialized products or services to other companies or individuals.

Their business model involves developing proprietary therapeutic candidates through various clinical stages. If successful, these therapies would ultimately be prescribed by healthcare professionals to patients and distributed through pharmaceutical channels, potentially through partnerships with larger pharmaceutical companies for commercialization.

Therefore, Tenaya Therapeutics does not have "major customers" as described in the request.

AI Analysis | Feedback

null

AI Analysis | Feedback

Faraz Ali, Chief Executive Officer

Mr. Ali joined Tenaya Therapeutics as Chief Executive Officer in June 2018. Prior to Tenaya, he served as Chief Business Officer at REGENXBIO, where he was responsible for corporate development, commercial planning, portfolio strategy, alliance management, and corporate communications. He was also a Vice President at bluebird bio, overseeing new product planning, program management, patient advocacy, and external affairs. Earlier in his career, Mr. Ali held increasing global commercial leadership roles at Genzyme Corporation, contributing to the launch of multiple first-in-class enzyme replacement therapies for rare diseases. He began his career at General Electric, with technical roles at GE Healthcare and business assignments at GE Corporate. Mr. Ali received his MBA from Harvard Business School and his B.S. from Stanford University. Tenaya Therapeutics was backed by The Column Group, a venture capital firm, when Mr. Ali was appointed CEO. He also served as a consultant for Third Rock Ventures, another venture capital firm.

Tomohiro Higa, Senior Vice President, Finance and Interim Principal Accounting Officer

Mr. Higa serves as Tenaya's Senior Vice President, Finance and Interim Principal Accounting Officer. He joined Tenaya in 2020 as Vice President and Head of the Finance department, bringing over 20 years of experience in finance roles within biopharmaceutical companies. During his tenure at Tenaya, he has been instrumental in establishing key financial systems and processes, including guiding the company through its transition from a private to a public entity, and directing its financial planning activities. Before joining Tenaya, Mr. Higa was a Senior Director, Finance at CytomX Therapeutics, Inc.

Whit Tingley, M.D., Ph.D., Chief Medical Officer

Dr. Tingley became Tenaya's Chief Medical Officer in December 2018. His previous roles include Vice President of Clinical Development, Cardiology, at Cytokinetics, and nine years at Genentech/Roche, where he advanced to Therapeutic Area Lead for Cardiovascular and Metabolism Research and Early Development. Dr. Tingley also served as an adjunct associate professor of medicine in the cardiology division at the University of California, San Francisco (UCSF) and worked as an attending cardiologist. He earned his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Kee-Hong Kim, Ph.D., Chief Technology Officer

Dr. Kim is the Chief Technology Officer at Tenaya Therapeutics. He joined the company in March 2019 as Senior Vice President of Manufacturing and Technical Operations. Prior to Tenaya, Dr. Kim was Senior Vice President, Head of Technical Operations, at Agilis Biotherapeutics, where he was responsible for gene therapy drug product manufacturing and establishing clinical and commercial supply chains. He also held positions as Head of Gene Therapy Process Development and Global CMC Lead of Gene Therapy at Shire, and previously led his own biopharma consulting firm after serving as Director of Process Development at Avalanche Biotechnology (now Adverum).

Kathy Ivey, Ph.D., Senior Vice President, Research

Dr. Ivey holds the position of Senior Vice President, Research, at Tenaya Therapeutics. She was promoted to this role in 2024 and is responsible for leading all non-clinical research and discovery initiatives at the company.

AI Analysis | Feedback

The key risks to Tenaya Therapeutics (TNYA) are as follows:

1. Clinical Development and Regulatory Approval Risk: As a biotechnology company primarily engaged in research and development, Tenaya Therapeutics' success hinges on its ability to successfully advance its numerous product candidates (including TN-201, TN-301, and TN-401) through preclinical and clinical trials and ultimately secure regulatory approvals. Failures in clinical trials, unexpected safety concerns, or an inability to obtain regulatory clearances for its therapies would significantly and adversely impact the business, as the company currently has no commercialized products.
2. Competition: The therapeutic area of heart disease is highly competitive, with established pharmaceutical companies and other biotechnology firms actively developing treatments for conditions such as genetic hypertrophic cardiomyopathy (gHCM), heart failure with preserved ejection fraction (HFpEF), genetic dilated cardiomyopathy (gDCM), and arrhythmogenic right ventricular cardiomyopathy (gARVC). The potential for existing or new competitors to develop more effective, safer, or more cost-efficient therapies could limit the market opportunity and commercial success of Tenaya's product candidates, even if approved.
3. Funding and Capital Requirements: The discovery, development, and delivery of novel therapies, particularly complex gene therapies, are capital-intensive processes. Tenaya Therapeutics is engaged in multiple expensive programs, and its ability to continue funding its extensive research and development efforts, conduct clinical trials, and pursue regulatory approvals relies on securing substantial ongoing financing. A failure to raise sufficient capital on acceptable terms could lead to delays, curtailment, or even abandonment of its development programs.

AI Analysis | Feedback

AI Analysis | Feedback

For Tenaya Therapeutics (TNYA), the addressable markets for their main products are as follows:

• TN-201 (MYBPC3-associated hypertrophic cardiomyopathy (gHCM)): Null
• TN-301 (Heart failure with preserved ejection fraction (HFpEF)): The global congestive heart failure drugs market, which includes HFpEF, was valued at approximately USD 18 billion in 2024 and is projected to reach USD 53.9 billion by 2034.
• TN-301 (Genetic dilated cardiomyopathy (gDCM)): The global dilated cardiomyopathy therapeutic market was estimated at approximately USD 397.54 million in 2026, with projections to reach USD 488.01 million by 2031. In 2023, the US market for dilated cardiomyopathy was approximately USD 329.4 million. Genetic and familial etiologies constituted 32.45% of the dilated cardiomyopathy therapeutic market share in 2025.
• TN-401 (PKP2-associated arrhythmogenic right ventricular cardiomyopathy (gARVC)): More than 70,000 people in the U.S. alone are estimated to have PKP2-associated ARVC.
• AAV-based gene therapy (DWORF gene in the heart for DCM): The global dilated cardiomyopathy therapeutic market was estimated at approximately USD 397.54 million in 2026, with projections to reach USD 488.01 million by 2031. In 2023, the US market for dilated cardiomyopathy was approximately USD 329.4 million.
• Reprogramming program (cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction): The global myocardial infarction (MI) therapeutics market size was valued at USD 22.73 billion in 2024 and is projected to grow to USD 33.78 billion by 2033.

AI Analysis | Feedback

• Commercialization of Lead Gene Therapies (TN-201 and TN-401): Tenaya's lead gene therapy candidates, TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), have shown promising interim clinical data. The company plans to engage with regulatory bodies throughout 2026 to align on pivotal study pathways for both programs, with updates expected in the latter half of the year. Successful progression through these regulatory discussions and subsequent clinical development could pave the way for potential commercialization, which analysts project could generate significant revenue for Tenaya in 2027 and 2028.
• Advancement and Potential Commercialization of Small Molecule TN-301: Tenaya's small molecule HDAC6 inhibitor, TN-301, is being developed for heart failure with preserved ejection fraction (HFpEF), genetic dilated cardiomyopathy (gDCM), and Duchenne Muscular Dystrophy (DMD). Preclinical studies have demonstrated TN-301's efficacy in DMD models, restoring muscle performance and correcting cardiac defects. Following positive Phase 1 safety data, Tenaya intends to advance TN-301 into Phase 2 clinical development in 2026, targeting HFpEF and DMD as prioritized indications. The successful progression and eventual commercialization of TN-301 would diversify Tenaya's revenue streams beyond its gene therapy programs.
• Milestone Payments from Alnylam Pharmaceuticals Collaboration: Tenaya has established a multi-target research collaboration with Alnylam Pharmaceuticals aimed at identifying and validating novel gene targets for cardiovascular diseases. This partnership includes an upfront payment of up to $10 million and the potential for over $1.1 billion in milestone payments. These milestone payments, contingent on the achievement of specific development and regulatory events, represent a significant non-product revenue driver for Tenaya over the next few years.
• Potential for Accelerated Regulatory Approvals: Encouraging trends observed in the clinical data for Tenaya's gene therapy programs, such as improvements in left ventricular mass index (LVMI) and vector copy number (VCN), may support the possibility of accelerated regulatory approvals for its therapies. Expedited approval pathways could significantly shorten the time to market, allowing Tenaya to generate product revenue sooner than conventional development timelines.

AI Analysis | Feedback

Share Issuance

• In December 2025, Tenaya Therapeutics closed an underwritten public offering of 50,000,000 units, each consisting of one share of common stock and a warrant, generating net proceeds of $55.8 million.
• The company completed a public offering in March 2025, which netted approximately $48.8 million.
• Tenaya's Initial Public Offering (IPO) in July 2021 resulted in a significant capital infusion, raising $150 million.

Inbound Investments

• In March 2026, Tenaya entered into a multi-target research collaboration with Alnylam Pharmaceuticals, which includes an upfront payment of up to $10.0 million and potential development, regulatory, and sales-based milestones totaling up to $1.13 billion.

Capital Expenditures

• In the last 12 months (prior to March 2026), capital expenditures were -$755,000.
• Capital expenditures in Q3 2025 were $26,000, focused on funding long-term assets and infrastructure.
• In 2025, Tenaya decommissioned its internal manufacturing center (GMMC) and transitioned to third-party contract development and manufacturing organizations (CDMOs) as a cost-saving measure.